Table 2—

Prevalence and titer of circulating islet cell-specific autoantibodies in patients with LADA, adult-onset type 1 diabetes, and type 2 diabetes and in patients with newly diagnosed LADA and those with adult-onset and childhood-onset type 1 diabetes

AutoantibodyLADAAdult-onset type 1 diabetesType 2 diabetesNewly diagnosed LADANewly diagnosed adult-onset type 1 diabetesNewly diagnosed childhood-onset type 1 diabetes
n5457190213748
ICA only18 (33)8 (14)5 (3)6 (29)6 (16)2 (4)
GADA only14 (26)5 (9)4 (2)6 (29)1 (3)2 (4)
IA-2A only000003 (6)
ICA + GADA12 (22)11 (19)04 (19)8 (22)10 (21)
ICA + IA-2A01 (2)001 (3)6 (13)
GADA + IA-2A1 (2)2 (3)01 (5)01 (2)
ICA + GADA + IA-2A9 (17)18 (32)04 (19)17 (46)23 (48)
Antibody negative012 (21)181 (95)04 (11)1 (2)
ICA and/or GADA and/or IA-2A54459213347
Titer of ICA (JDF)NENENE20 (0–40)30 (10–40)40 (20–50)
Titer of GADA (units/ml)NENENE2.4 (0.7–29.8)12.5 (0.8–50.1)3.1 (0.9–8.1)
Titer of IA-2A (units/ml)NENENE0.4 (0.2–3.8)0.7 (0.3–5.2)4.3 (0.6–18.1)
  • Data are n (%), n, or median (interquartile range). The prevalence of circulating islet cell-specific autoantibodies was compared by Fisher’s exact test. The titer of autoantibodies was compared by Mann-Whitney test. For statistical significance among the groups, see the text. NE, not evaluated.